One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

NCT02962284 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: abiraterone acetate with Methylprednisolone

Sponsor

Sun Pharmaceutical Industries Limited